Literature DB >> 15640840

Structure and function of Polo-like kinases.

Drew M Lowery1, Daniel Lim, Michael B Yaffe.   

Abstract

Polo-like kinases play critical roles during multiple stages of cell cycle progression. All Polo-like kinases contain an N-terminal Ser/Thr kinase catalytic domain and a C-terminal region that contains one or two Polo-boxes. For Polo-like kinase 1, 2, and 3, and their homologs, the entire C-terminal region, including both Polo-boxes, functions as a single modular phosphoserine/threonine-binding domain known as the Polo-box domain (PBD). In the absence of a bound substrate, the PBD inhibits the basal activity of the kinase domain. Phosphorylation-dependent binding of the PBD to its ligands releases the kinase domain, while simultaneously localizing Polo-like kinases to specific subcellular structures. These observations suggest two different models for how the PBD integrates signals arising from other mitotic kinases to target the activated kinase towards distinct substrates. The recent X-ray crystal structures of the PBD provide insights into the structural basis for PBD function and kinase regulation. Molecular modelling of the structure of the isolated kinase domain reveals a potential basis for motif-dependent substrate specificity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15640840     DOI: 10.1038/sj.onc.1208280

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  134 in total

1.  Plk1-mediated phosphorylation of UAP56 regulates the stability of UAP56.

Authors:  Fuyin Xiong; Yanli Lin; Zhengbin Han; Gengshou Shi; Liyuan Tian; Xiaojie Wu; Qiangcheng Zeng; Yanrong Zhou; Jixian Deng; Hongxing Chen
Journal:  Mol Biol Rep       Date:  2011-06-03       Impact factor: 2.316

Review 2.  Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy.

Authors:  Kyung S Lee; Terrence R Burke; Jung-Eun Park; Jeong K Bang; Eunhye Lee
Journal:  Trends Pharmacol Sci       Date:  2015-10-17       Impact factor: 14.819

3.  Structure-function relationship of the Polo-like kinase in Trypanosoma brucei.

Authors:  Zhonglian Yu; Yi Liu; Ziyin Li
Journal:  J Cell Sci       Date:  2012-01-24       Impact factor: 5.285

4.  Dbf4 regulates the Cdc5 Polo-like kinase through a distinct non-canonical binding interaction.

Authors:  Ying-Chou Chen; Michael Weinreich
Journal:  J Biol Chem       Date:  2010-10-29       Impact factor: 5.157

5.  Cdc7-Dbf4 phosphorylates MCM proteins via a docking site-mediated mechanism to promote S phase progression.

Authors:  Yi-Jun Sheu; Bruce Stillman
Journal:  Mol Cell       Date:  2006-10-06       Impact factor: 17.970

6.  A coupled chemical-genetic and bioinformatic approach to Polo-like kinase pathway exploration.

Authors:  Jennifer L Snead; Matthew Sullivan; Drew M Lowery; Michael S Cohen; Chao Zhang; David H Randle; Jack Taunton; Michael B Yaffe; David O Morgan; Kevan M Shokat
Journal:  Chem Biol       Date:  2007-11

7.  A microtubule-independent role for centrosomes and aurora a in nuclear envelope breakdown.

Authors:  Nathan Portier; Anjon Audhya; Paul S Maddox; Rebecca A Green; Alexander Dammermann; Arshad Desai; Karen Oegema
Journal:  Dev Cell       Date:  2007-04       Impact factor: 12.270

8.  Mutual regulation between Polo-like kinase 3 and SIAH2 E3 ubiquitin ligase defines a regulatory network that fine-tunes the cellular response to hypoxia and nickel.

Authors:  Cen Li; Soyoung Park; Xiaowen Zhang; Wei Dai; Dazhong Xu
Journal:  J Biol Chem       Date:  2017-05-17       Impact factor: 5.157

9.  Structure and substrate recruitment of the human spindle checkpoint kinase Bub1.

Authors:  Jungseog Kang; Maojun Yang; Bing Li; Wei Qi; Chao Zhang; Kevan M Shokat; Diana R Tomchick; Mischa Machius; Hongtao Yu
Journal:  Mol Cell       Date:  2008-11-07       Impact factor: 17.970

10.  Targeting subcellular localization through the polo-box domain: non-ATP competitive inhibitors recapitulate a PLK1 phenotype.

Authors:  Campbell McInnes; Kara Estes; Merissa Baxter; Zhengguan Yang; Doaa Boshra Farag; Paul Johnston; John S Lazo; Jianjun Wang; Michael D Wyatt
Journal:  Mol Cancer Ther       Date:  2012-07-30       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.